therapeutic efficacy once-daily oral administration kunitz-type protease inhibitor bikunin mouse model human cancer pubmed ncbi abstract background bikunin kunitz-type protease inhibitor specifically inhibits tumor invasion metastasis methods authors initially evaluated therapeutic efficacy once-daily oral administration doses bikunin human ovarian carcinoma hra cells growing peritonea nude mice vivo studies female num week-old nude mice randomized num num groups bikunin-treated groups num group received num num microg/g body weight day bikunin num days gastrointestinal gavage control group num received vehicle solution phosphate-buffered saline gastrointestinal gavage day num abdominal cavity examined observers blinded treatment results oral administration intact bikunin detectable mouse serum specimens num num hours decline num hours mice bikunin highest dose level num decrease tumor load highest uptake tumor obtained num bikunin num hours postadministration effect food intake body weight observed treated versus sham groups current study report potent activity once-daily oral administration bikunin ovarian carcinoma authors performed phase trial determine maximum-tolerated dose mtd safety once-daily oral administration schedule indication locally advanced uterine cervical carcinoma definitive treatment escalating dose num num mg/kg day bikunin administered orally patients num days dose-limiting toxicities mtd bikunin schedule defined authors obtained preliminary data effect urokinase-type plasminogen activator expression highest dose level conclusions once-daily oral administration bikunin found safe humans exhibited signs biologic activity copyright num american cancer society 
